Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced the release of a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, one of the United Kingdom's leading private hospitals. The video, available here, highlights his experience using Nociscan to evaluate patients with chronic low back pain. To date, nearly 100 Nociscans have been conducted at The London Clinic, reflecting sustained physician engagement and growing integration into routine clinical practice.
Mr. Sutcliffe, who also serves as Lead Clinician at The London Spine Clinic, has over 30 years of experience treating spinal conditions. In the video, he notes that Nociscan provides an additional layer of insight that complements traditional imaging, offering more objective data to inform clinical decisions and improve confidence when evaluating patients. Nociscan is a non-invasive solution that uses MR spectroscopy and proprietary signal processing to identify chemical biomarkers associated with disc pain, helping physicians differentiate between painful and non-painful discs in the lumbar spine.
Chronic low back pain affects approximately 266 million people worldwide, representing a significant global healthcare challenge. When used alongside other diagnostic tools, clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated. Brent Ness, Chief Executive Officer of Aclarion, stated, “Approaching 100 scans at a leading international center like The London Clinic is an important indicator of increasing adoption and reinforces the potential for Nociscan to become a valuable tool in the evaluation of chronic low back pain.”
The continued use of Nociscan at The London Clinic underscores its potential to improve patient outcomes by providing critical insights into the location of pain, enabling physicians to optimize treatment strategies. For more information, visit www.aclarion.com or view the latest news here. To find a Nociscan center, see the site map here.
This announcement follows Aclarion's commitment to leveraging biomarkers and augmented intelligence to address chronic low back pain, with Nociscan as the first evidence-supported SaaS platform to noninvasively aid in disc pain diagnosis. The company's forward-looking statements highlight expectations for continued adoption, though actual results may differ due to risks detailed in SEC filings.
